Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00098839

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Sponsor: Children's Oncology Group

Conditions Recurrent Childhood Acute Lymphoblastic Leukemia

Interventions L-asparaginase cyclophosphamide cytarabine dexrazoxane hydrochloride doxorubicin hydrochloride epratuzumab etoposide filgrastim leucovorin calcium methotrexate pegaspargase prednisone therapeutic hydrocortisone vincristine sulfate

Updated 9 times since 2017 Last updated: Nov 14, 2017 Started: Feb 28, 2005 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Recurrent Childhood Acute Lymphoblastic Leukemia, this trial is completed. The trial is conducted by Children's Oncology Group and has accumulated 9 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 4 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
May 2017 — Dec 2017 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Oncology Group
National Cancer Institute (NCI)

Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Bangor, United States , Birmingham, United States , Boston, United States , Charleston, United States , Columbus, United States and 32 more locations